

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

PCT / CA 99/00287

30 APR 1999 (30.04.99)

09/647981

REC'D 11 MAY 1999

WIPO

PCT

5

0401643

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

April 23, 1999

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 09/055,744

FILING DATE: April 7, 1998

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)



By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS

H. Phillips
H. PHILLIPS

Certifying Officer

1. The first part of the paper is devoted to a review of the literature on the topic. It starts with a general overview of the field, followed by a more detailed discussion of the specific issues at hand. The author then presents his own findings, which are based on a series of experiments. Finally, he concludes with some thoughts on the implications of his work.

HIV-SPECIFIC CYTOTOXIC T-CELL RESPONSES

5 The present invention relates to immunology and, in particular, to generating an HIV-specific T-cell response in a host.

Acquired immunodeficiency syndrome (AIDS) is a disease which is the ultimate result of infection with human immunodeficiency virus (HIV). Currently, there is no effective vaccine which can protect the human population from HIV infection and hence the development of an efficacious HIV-vaccine and protocol for administering the same is urgently required. Previously, HIV-1 particles exhaustively inactivated by chemical treatments, a vaccinia vector encoding the whole envelope protein (gp160) of HIV-1, and purified recombinant gp120 have been evaluated as candidate HIV vaccines. Although inactivated HIV-1 virus preparations elicited a T-cell-mediated Delayed-Type Hypersensitivity (DTH) reaction in humans, and vaccinia/gp160 and gp120 recombinant vaccine candidates induced virus neutralizing antibodies, none of these immunogens have been shown to be efficacious human HIV vaccines. The inventors' interest in HIV vaccinology is to develop synthetic HIV-1 peptide vaccines and consider that their use alone or in conjunction with other HIV-1 vaccine candidates may lead to the elicitation of more effective immune responses against HIV-1.

The inventors' had previously described in their granted European Patent No. 470,980 and U.S. Patent No.

5,639,854, the disclosures of which are incorporated herein by reference, *inter alia*, the identification and characterization of a T-cell epitope of the core protein, p24E, of HIV-1, and its usage in the construction of immunogenic synthetic chimeric peptides comprising p24E linked to amino acid sequences of different B-cell epitopes of an envelope or core protein of HIV-1.

The present effort has turned to the design of HIV vaccines capable of eliciting cell-mediated immunity (CMI) and protocols for the use thereof. In this context, the inventors have focused interest on a viral protein, Rev, expressed early during the life cycle of the HIV-virus, for the reason that the carboxyl terminal half is rich in human cytotoxic T-cell (CTL) motifs. Peptides which are generated via immunization with an appropriately constructed vaccine containing the Rev protein, therefore, may be presented in the context of the Major Histocompatibility Complex (MHC) class 1 molecules to induce CTL effector responses capable of killing virus infected cells early to limit virus spread. However, the immunization protocol provided herein is applicable to T-cell epitope containing peptides derived from other HIV proteins.

SUMMARY OF THE INVENTION

In accordance with one aspect of the present invention, there is provided a method of generating an HIV-specific cytotoxic T-cell (CTL) response in a host, which comprises:

administering to the host a T-helper molecule to prime T-helper cells of the immune system of the host, and

subsequently administering to the host a mixture of said T-helper molecule and a T-cell inducing HIV-

derived molecule to generate an HIV-specific T-cell response in the host.

Accordingly, the immune system of the host, which may be a human host, is primed by any convenient T-helper molecule and then there is subsequently administered the T-helper molecule in admixture with a T-cell inducing molecule. In this way, an HIV-specific T-cell response is obtained.

The T-helper molecule may be any of the materials well known to provide such MHC class II-helper activity in the immune system, including T-cell human DP, DR, DQ-specific T-cell epitopes. The material used in the experimentation described herein is a peptide which corresponds to a portion of the hepatitis B virus nucleocapsid antigen, identified as CLP-243 (SEQ ID NO: 10). The T-helper molecule may be administered with an adjuvant, if desired.

The T-cell inducing HIV-derived molecule generally includes a peptide corresponding to a portion of a HIV-1 antigen and containing at least one T-cell epitope. In particular, the peptides may correspond to sequences of the Rev protein of HIV-1, particularly corresponding to amino acids 52 to 116 (SEQ ID NO:9) (Table 2) of HIV-1 (LAI) Rev (CLP-164). The amino acid sequence of Rev protein is that of the LAI isolate. The invention includes the use of corresponding peptides sequences from Rev proteins from other HIV-1 isolates, including primary isolates.

In the experimentation described herein, the peptide was effective in the protocol described herein when provided in the form of a lipopeptide, particularly when the lipid is palmitoyl or cholesterol. Two particular lipopeptides used herein

are CLP-175 and CLP-176 being the palmitoyl and cholesterol derivatives, respectively, of CLP-164.

The mixtures of the T-helper molecule and T-cell inducing HIV-derived molecule may be administered with a suitable adjuvant.

The present invention further provides, in another aspect, certain novel peptides derived from the Rev protein of HIV-1. Accordingly, in this aspect of the invention, there is provided a peptide having an amino acid sequence corresponding to amino acids 52 to 116 (SEQ ID NO:9) of the sequence of the Rev protein of HIV and containing T-cell epitopes within amino acids 65 to 75 (SEQ ID NO:3), 78 to 87 (SEQ ID NO:5) and 102 to 110 (SEQ ID NO:8) (Table 1). Such peptide may be provided in the form of a lipopeptide including CLP-175 or CLP-176. The specific amino acid sequences of the peptide having SEQ ID NO:9 is that for the LAI isolate of HIV-1. Included within the scope of the invention is the corresponding peptide and corresponding T-cell epitope sequences of the Rev protein of other HIV-1 isolates, including primary isolates.

Advantages of the present invention include:

- an immunization procedure to induce a T-cell response in a host
- immunogenic peptides for use in such procedure.

BRIEF DESCRIPTION OF DRAWINGS

Figure 1 illustrates the results of *in vitro* HLA-A2 stabilization experiments conducted using certain Rev-derived peptides by FACS (fluorescent antibody cell sorting). Peptide CLP-72 (SEQ ID NO:8), CLP-182 (SEQ ID NO:7), CLP-178 (SEQ ID NO:3) and CLP-177 (SEQ ID NO:2) bound to HLA-A2 on T2 cells as shown by shifting of the respective fluorescent peaks.

Figure 2, comprising panels A to F, illustrates the immunogenicity of HIV-1 (LAI) Rev immunogens in A2Kb transgenic mice using CLP-175, 176 and 164 (SEQ ID NO:9), with or without priming with CLP-243 (SEQ ID NO:10).

Figure 3, comprising panels A to X, illustrates the HIV-1 (LAI) Rev-specific CTL induction in A2Kb transgenic mice employing various protocols as described below.

10

DETAILED DESCRIPTION OF INVENTION

The inventors have found that two nanomer peptides, designated CLP-177 (SEQ ID NO:2) and CLP-72 (SEQ ID NO:8), a hexamer designated CLP-178 (SEQ ID NO:3), and a 12-mer designated CLP-182 (SEQ ID NO:7) of the HIV-1(LAI) Rev protein (the amino acid sequences appear in Table 1), were individually able to bind and stabilize membrane-bound the Human Major Histocompatibility Complex (HLA) class 1 molecules, HLA-A2, which is the predominant HLA class 1 subtype found in caucacians. The inventors have also found that a long peptide (SEQ ID NO:9), encompassing the amino acid residues 52 to 116 of the HIV-1(LAI) Rev protein, and constructed by having a single cholesterol or palmitoyl moiety attached to its amino-(N-) terminus via a KSS linker to form lipopeptides, CLP-176 and CLP-175 respectively, is also capable of eliciting CTL as well as antibody responses in HLA-A2 transgenic mice.

On the basis of the experimentation provided herein, there is provided hereby a novel immunization protocol for inducing a HIV-specific cytotoxic T-cell response in a host by initial administration of a T-helper molecule to prime the immune system of the host followed by administration of a mixture of the T-helper

molecule and a T-cell epitope-containing peptide corresponding to a portion of an HIV antigen.

The invention is illustrated herein by using, as the T-helper molecule, a peptide which corresponds to a portion of the hepatitis B virus nucleocapsid antigen.

However, other T-helper molecules may be employed, such as those providing MHC class II-helper activity in the immune system.

The invention is illustrated herein by using, as the HIV T-cell epitope containing peptide, certain lipopeptides derived from the Rev protein. However, HIV T-cell epitope containing peptides derived from any other HIV proteins may be employed.

One model has recently been used to predict human CTL antigenic determinants on the basis of the primary sequence (see references 1 to 3, throughout this specification, various references are referred to in parenthesis to more fully describe the state of the art to which this invention pertains. Full bibliographic information for each citation is found at the end of the specification, immediately following the claims. The disclosures of these references are hereby incorporated by reference into the present disclosure). It has been proposed that CTL epitopes which are most favoured to bind and lodge into the peptide-binding groove of the human MHC class I molecule, such as HLA-A2, is usually 9 amino acids long. However, peptides containing 8 to 13 amino acids able to interact with HLA class I molecules have also been reported. In the majority of cases, these peptides are found to contain a leucine (L) or methionine (M) residue at position 2, and either L or valine (V) at their carboxy-terminal ends.

Location of the potential CTL containing motifs of the HIV-1(LAI) Rev protein has been predicted by the

reported peptide-binding motif algorithms. Table 1 shows the amino acid sequences of such predicted peptides (SEQ ID NOS: 1 to 8). The ability of the peptides containing these motifs to bind and stabilize membrane-bound HLA-A2 molecule was assessed using the T2 cell line. The cell line has been well documented to have defective TAP transporter function resulting in the majority of the intracellularly generated peptides being unable to be transported into the endoplasmic reticulum to associate with the newly synthesized HLA class 1 molecules, i.e. HLA-A2 (see references 4, 5). The majority of the HLA-A2 molecules displayed on the surface of the T2 cells are, therefore, empty (i.e. contain no peptides) and are unstable. Upon interaction with suitable peptides introduced exogenously, the stability of the HLA-A2 molecules can be restored.

The results of *in vitro* HLA-A2 stabilization experiments conducted herein demonstrated that two nanomers, namely, CLP-177 (SEQ ID NO:2) and CLP-72 (SEQ ID NO:8); and a 11-mer and a 12-mer represented by the peptides, namely CLP-178 (SEQ ID NO:3) and CLP-182 (SEQ ID NO:4) respectively; were capable of binding to HLA-A2 on T2 cells. This result was shown by shifting of the respective fluorescent peaks to the right due to higher density of class 1 molecules displayed on the cells, as shown in accompanying Figure 1. A comparison of the respective fluorescence indices revealed that the potency of the peptides is in the order of CLP-177 > CLP-72 > CLP-178 > CLP-182.

The constructions of lipidated Rev peptides which were tested are shown in Table 2. The results depicted in Figure 2 illustrate that lipidated Rev 52 to 116 (SEQ ID NO:9) peptides, CLP-175 and CLP-176; as well as their non-lipidated counterpart, CLP-164, were

immunogenic, as determined by IgG titre, when injected three times at a dose of 100.0 µg into the A2Kb transgenic mice (ref. 6). High IgG antibodies directed against the Rev 52 to 116 peptide (CLP-164) were
 5 detected in animals administered with Incomplete

Freund's Adjuvant (IFA)-formulated CLP-175, or CLP-176 or CLP-164 (Panels A, B and C). Mice tested under a different experimental setting by priming them with a dose of CLP-243 in IFA, followed by boosting twice with
 10 a mixture of IFA-formulated CLP-243 + CLP-175, or CLP-243 + CLP-176 or CLP-243 + CLP-164, similarly elicited a high anti-CLP-164 antibody response (Panels D to F). CLP-243 is an I-A^b-restricted peptide encompassing the amino acids residues 128 to 140 (TPPAYRPPNAPIL; SEQ ID
 15 NO:10) of the hepatitis B virus nucleocapsid antigen (ref. 6).

The results of the immunogenicity experiments demonstrating that the lipopeptides, CLP-176 and CLP-175, were CTL-inducing are shown in Figure 3. A2Kb
 20 transgenic mice primed subcutaneously with a dose of the I-A^b-restricted peptide, CLP-243 in IFA, and boosted twice using the same immunization route with a mixture of the priming dose of CLP-243 and either 100.0 µg of CLP-176 or CLP-175 in IFA were found to generate
 25 effector cells killing the Jurkat-A2Kb target cells pulsed with the nanomer, CLP-177 (Panels A, B, E, F). The cytotoxic activity of the effectors were specific because Jurkat A2Kb cells not loaded with CLP-177 were not killed (Panels C, D, G and H). In contrast, the
 30 A2Kb transgenic animals injected similarly once with the CLP-243/IFA inoculum, then twice with CLP-243 plus CLP-164 in IFA, failed to elicit a significant CLP-177-specific effector response (Panels I, J, K, L).

The results of immunization experiments demonstrating that priming with the I-A^b-restricted peptide, CLP-243, followed by boosting with a mixture of CLP-243 and CLP-176 or CLP-175, was more effective than immunization with the respective lipopeptide alone for the induction of CTL response are shown in Figure 3. It was found that splenocytes of A2Kb transgenic mice injected 3 times subcutaneously with a dose of 100.0 µg of CLP-176, or CLP-175, or CLP-164 (the non-lipidated Rev 52-116) in IFA, and re-stimulated with CLP-177 pulsed Jurkat A2Kb cells and exogenously added CLP-175 at a concentration of 15.0 µg per ml did not result in the generation of effectors capable of killing Jurkat cells pulsed with the CLP-177 peptide (Panels M to X).

The results of the *in vitro* re-stimulation experiments showed that the simultaneous re-stimulation of the CLP-243-specific I-A^b-restricted T-helper cells achieved by the addition of the CLP-243 peptide, and the CLP-177-specific effectors achieved by co-culturing them with CLP-177-pulsed Jurkat A2Kb cells was required to augment the enrichment of the CLP-177-specific effectors to allow their detection in the *in vitro* CTL assay.

The components are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective, immunogenic and protective in the immunization protocol. The quantity of material to be administered depends on the subject to be treated, including, for example, the capacity of the immune system of the individual to synthesize antibodies, and to produce a cell-mediated immune response. Precise amounts of active ingredient required to be administered depend on

the judgement of the practitioner. However, suitable dosage ranges are readily determinable by one skilled in the art and may be of the order of micrograms to milligrams of material. The dosage may also depend on the route of administration and will vary according to the size of the host.

Immunogenicity can be significantly improved if the antigens are co-administered with adjuvants. Adjuvants enhance the immunogenicity of an antigen but are not necessarily immunogenic themselves. Adjuvant may act by retaining the antigen locally near the site of administration to produce a depot effect facilitating a slow, sustained release of antigen to cells of the immune system. Adjuvants can also attract cells of the immune system to an antigen depot and stimulate such cells to elicit immune response.

Immunostimulatory agents or adjuvants have been used for many years to improve the host immune responses to, for example, vaccines. Intrinsic adjuvants, such as lipopolysaccharides, normally are the components of the killed or attenuated bacteria used as vaccines. Extrinsic adjuvants are immunomodulators which are typically non-covalently linked to antigens and are formulated to enhance the host immune responses. Thus, adjuvants have been identified that enhance the immune response to antigens delivered parenterally. Some of these adjuvants are toxic, however, and can cause undesirable side-effects, making them unsuitable for use in humans and many animals. Indeed, only aluminum hydroxide and aluminum phosphate (collectively commonly referred to as alum) are routinely used as adjuvants in human and veterinary vaccines. The efficacy of alum in toxoids is well

established and a HBsAg vaccine has been adjuvanted with alum.

A wide range of extrinsic adjuvants can provoke potent immune responses to antigens. These include
5 aluminum phosphate, aluminum hydroxide, QS21, Quil A, derivatives and components thereof, calcium phosphate, calcium hydroxide, zinc hydroxide, a glycolipid analog, an octodecyl ester of an amino acid, a muramyl dipeptide, polyphosphazene, a lipoprotein, ISCOM
10 matrix, DC-Chol, DDBA, and other adjuvants and bacterial toxins, components and derivatives thereof. Particularly advantageous combination are described in copending U.S. Application No. 08/258,228 filed June 13, 1994 and 08/483,856 filed June 7, 1995, assigned to
15 the assignee hereof and the disclosure of which is incorporated herein by reference thereto (WO 95/34308). Under particular circumstances adjuvants that induce a Th1 response are desirable.

The invention is further illustrated by the
20 following Examples.

The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific Examples. These Examples are described solely for
25 purposes of illustration and are not intended to limit the scope of the invention. Changes in form and substitution of equivalents are contemplated as circumstances may suggest or render expedient. Although specific terms have been employed herein, such terms are
30 intended in a descriptive sense and not for purposes of limitation.

EXAMPLES

Methods of peptide and lipopeptide synthesis, cell culture, enzyme immunoassays (EIA), CTL assay and other

testing procedures that are not explicitly described in this disclosure are amply reported in the scientific literature and are well within the scope of those skilled in the art.

5 Example 1:

 This Example illustrates the synthesis of peptides and lipopeptides.

 Solid phase peptide syntheses were conducted on an
10 ABI 430A automated peptide synthesizer according to the
 manufacturer's standard protocols. The amino acid
 sequences of the synthesized peptides are shown in
 Table 1 below.

 Lysine residues designed for subsequent lipidation
15 were incorporated in the peptides by using N^a-t-
 butyloxycarbonyl-N^e-fluorenylmethoxycarbonyl-lysine
 (Boc-Lys(Fmoc)-OH). The lipid moieties were
 incorporated by manual removal of the side chain Fmoc
 protecting group followed by acylation with the
 appropriate carboxylic acid activated with O-
20 benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexa-
 fluorophosphate (HBTU) and diisopropylethylamine in
 dimethylformamide (DMF). The lipopeptides were cleaved
 from the solid support by treatment with liquid
 hydrogen fluoride in a presence of thiocresole, anisole
25 and methyl sulfide. The crude products were extracted
 with trifluoroacetic acid (TFA) and precipitated with
 diethyl ether. The lipopeptides and the unlipidated
 peptides are shown in Table 2.

Example 2:

30 This Example illustrates the method used to
 demonstrate the HLA-A2 binding and modulation of
 peptides.

 T2 cell line expressing the HLA-A2 molecules was
 obtained from Dr Peter Creswell at the Howard Hughes

Research Institute of Yale University. The cells were propagated in Iscove's complete medium (Iscove's medium supplemented with 10% heat-inactivated bovine serum, 120.0 units per ml of penicillin G sodium, 120 µg per ml of streptomycin sulphate, and 0.35 mg per ml of L-glutamine). The ability of individual 8 to 13 mer peptides, prepared as described in Example 1 and identified in Table 1, to bind and modulate the stability of the A2 molecules on T2 cells was determined using a peptide-induced MHC class 1 assembly assay, which was modified from a protocol described by Yuping Deng et al. (ref. 6).

In essence, 1×10^6 T2 cells were incubated with a specified concentration of the test peptide in 250.0 µl of Iscove's serum-free medium (Iscove's medium supplemented with 120.0 units per ml of penicillin G sodium, 120.0 µg per ml of streptomycin sulphate and 0.35 mg per ml of L-glutamine) in a sterile Eppendorf tube at 37°C overnight. The cells were then incubated on ice for 30 min before 1.0 ml of Iscove's complete medium supplemented with 5.0 µg per ml of brefeldin A, 12.5 µg per ml of anisomycin and 5.0 µg per ml of cyclohexamide was added. The samples were then incubated for 3.0 hr in a 37°C CO₂ incubator.

In the presence of the drugs, further protein synthesis and intracellular delivery of HLA-A2 molecules to the cell surface are inhibited, and destabilization of the conformation of the membrane-bound class 1 molecules at the physiological temperature occurs.

The cells were then washed twice with ice-cold PBA (a buffer containing 0.9% sodium chloride, 0.5% bovine serum albumin and 0.02% sodium azide). 100.0 µl of PBA containing 5.0 µg of a conformation-sensitive HLA-A2-

specific mouse monoclonal antibody, BB7.2 (ref. 7), was then added to each test sample. The reaction was allowed to take place on ice for 45 min. The cells were then washed three times with ice-cold PBA.

5 The binding of BB7.2 was then detected by adding 100.0 of PBA containing 1.0 ug of goat anti-mouse IgG F(ab') fluorescein (FITC) conjugate to each cell sample. After 30 min incubation on ice, the cells were washed twice with PBA, and twice again with PBS, pH 10 7.2. Cells were fixed immediately after washing was completed by adding 100.0 ul of 1.0% paraformaldehyde to the cell pellet. The cells were gently resuspended and were FACS analysed usually within three days after the experiments were completed.

15 The fluorescence index, which is an indicator for increased density of membrane-bound A2 molecules, was calculated by dividing the mean fluorescence of an experimental sample (peptide treated T2 cells) by the mean fluorescence of the control sample (T2 cells not 20 treated with peptide). The results obtained are set forth in Figure 1.

Example 3:

25 This Example describes the prime and boost protocol used to test the immunogenicity of the peptides and lipopeptides.

 Mice of the B10 background which were transgenic for the A2Kb chimeric gene were purchased and licensed from the Scripps Clinic in California, USA. The colony is kept in the Animal Service Facility in Pasteur 30 Merieux Connaught Canada.

 A first group of the mice were injected subcutaneously at the base of the tail with a dose of 100.0 ug of IFA-formulated peptide or lipopeptide emulsified in IFA and were then boosted at 30 days and

again at 42 to 48 days later with the same inoculum. A second group of mice were injected subcutaneously at the base of the tail with a dose of 100.0 µg of an IFA-formulated CLP-243 and were then boosted with an IFA-formulated mixture of the same dose of the priming immunogen and 100.0 ug of CLP-175, or CLP-176, or CLP-164.

Sera of the experimental animals collected on the 10th or 11th day post final-injection were assayed for CLP-164-specific IgG antibodies using a standard EIA. The results obtained are shown in Figure 2. Splenocytes of the experimental mice were simultaneously cultured to enrich for CTLs before assaying for effector activity, as described below.

15 Example 4:

This Example illustrates an *in vitro* culture method used to enrich for CTL effectors and CTL assay.

Splenocytes of the experimental A2Kb transgenic mice from Example 3 at 3.0×10^7 were co-cultured with 1.3 x 10⁷ A2Kb transfected Jurkat cells pulsed with the peptides CLP-175 or CLP 176 in 15.0 ml of complete medium (RPMI 1640 supplemented with 10.0% 56°C heat-inactivated bovine serum, 120.0 units per ml of penicillin G sodium, 120.0 ug per ml of streptomycin sulphate and 0.35 mg per ml of L-glutamine) per 25 cm² tissue culture flask. The I-A^b-restricted peptide, CLP-243, was also added at a concentration of 15.0 ug per ml at the initiation of the culture. The cultures were kept at 37°C in a CO₂ incubator for 7 days, and the responders were then tested against peptide-pulsed Jurkat A2Kb transfectant in a standard *in vitro* 4 hr CTL assay, as follows.

The responders were harvested from the 7-day cultures and washed twice with the complete medium.

The positive target was created by incubating 1×10^6 Jurkat A2Kb cells with 100.0 ug of the specified peptide for overnight in a 37°C CO₂ incubator. The target cells were then labelled with ⁵¹Cr at 250.0 uCi per 1×10^6 cells for 1.5 hr in the presence of 25.0 ug of the same test peptides. After washing twice with complete medium to remove excess of ⁵¹Cr, the targets were incubated at 2.5×10^3 with different numbers of the responders for 4 hr in a 37°C CO₂ incubator. Half amount of the supernatant was then removed and counted for radio-activity. The results obtained are shown in Figure 3.

SUMMARY OF THE DISCLOSURE

In summary of this disclosure, the present invention provides a novel protocol for achieving a HIV-specific CTL response in a host, including a human host, by a prime/boost procedure using T-helper molecules and lipidated peptides of HIV protein, as well as novel peptides and lipopeptides. Modifications are possible within the scope of the invention.

TABLE 1

HLA-A2-restricted CTL motifs of the HIV-1(LAI)Rev protein

	PEPTIDE	SEQUENCE	AMINO ACIDS	SEQ ID NO:
1.	CLP-279	DLIKAVRL	11-18	1
2.	CLP-177	YLGRSAEPV	65-73	2
3.	CLP-178	YLGRSAEPVPL	65-75	3
4.	CLP-179	QLPPLERL	78-85	4
5.	CLP-180	QLPPLERLIL	78-87	5
6.	CLP-181	PLQLPPLERL	76-85	6
7.	CLP-182	PLQLPPLERLIL	76-87	7
8.	CLP-72	ILVESPAVL	102-110	8

TABLE 2

HIV-1(LAI)Rev 52-116 lipopeptides/peptide tested

Lipopeptide/ peptide	Construction
CLP-175	K[Palmitoyl]SS-RQIHSISERILSTYLGRSAEPVPLQLPPLERLTL- -DCNEDCGTSGTQGVGSPQILVESPAVLESGTKE
CLP-176	K[cholesterol]SS-RQIHSISERILSTYLGRSAEPVPLQLPPLERLTL- -DCNEDCGTSGTQGVGSPQILVESPAVLESGTKE
CLP-164	RQIHSISERILSTYLGRSAEPVPLQLPPLERLTL- -DCNEDCGTSGTQGVGSPQILVESPAVLESGTKE (SEQ ID NO:9)

1. Ian A Wilson and Daved H Fremont. Seminars in Immunology, Vol 5, pp 75-80, 1993.
2. Kirsten Falk and Olaf Rotzschke. Seminars in Immunology, Vol 5, pp 81-94, 1993.
3. Victor H Engelhard. Current Opinion in Immunology, Vol 6, pp 13-23, 1994.
4. Salter R D and Creswell P. EMBO J., Vol 5, pp943, 1986.
5. Townsend A. et al. Nature, Vol 340, pp 443, 1989.
6. Yuping Deng et al. Journal of Immunology, Vol 158, pp 1507-1515, 1997.

1. Ian A Wilson and Daved H Fremont. Seminars in Immunology, Vol 5, pp 75-80, 1993.
2. Kirsten Falk and Olaf Rotzschke. Seminars in Immunology, Vol 5, pp 81-94, 1993.
3. Victor H Engelhard. Current Opinion in Immunology, Vol 6, pp 13-23, 1994.
4. Salter R D and Creswell P. EMBO J., Vol 5, pp943, 1986.
5. Townsend A. et al. Nature, Vol 340, pp 443, 1989.
6. Yuping Deng et al. Journal of Immunology, Vol 158, pp 1507-1515, 1997.

1. The first part of the document is a list of names and addresses, which appears to be a directory or a list of subscribers. The names are written in a cursive script, and the addresses are listed below them.

1. A method of generating an HIV-specific cytotoxic T-cell (CTL) response in a host, which comprises:

subsequently administering to the host a mixture of said T-helper molecule and a T-cell inducing HIV-derived molecule to generate an HIV-specific T-cell response in the host.

3. The method of claim 2 wherein said T-helper epitopes are selected from the group consisting of DP, DR and DQ-specific T-cell epitopes.

5. The method of claim 1 wherein said T-helper molecule is administered with an adjuvant.

7. The method of claim 5 wherein said peptide correspond to sequences of the Rev protein of HIV-1.

9. The method of claim 8 wherein the lipid is palmitoyl or cholesterol.

11. The method of claim 6 wherein said mixture is administered with an adjuvant.

13. The peptide of claim 12 in the form of a lipopeptide.

14. The peptide of claim 13 wherein the lipid is palmitoyl or cholesterol.

15. The peptide of claim 13 wherein the lipopeptide is CLP-175 or CLP-176.

ABSTRACT OF THE DISCLOSURE

A method of generating an HIV-specific cytotoxic T-cell response in a host involves an initial administration of a T-helper molecule to the host to
5 prime T-helper cells of the immune system of the host and a subsequent administration to the host of a mixture of the T-helper molecule and a T-cell inducing HIV-derived molecule to generate an HIV-specific T-cell response in the host.

05/07/90 14:44:00

Docket No.
1038-746 MIS:jfb

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

HIV-SPECIFIC CYTOTOXIC T-CELL RESPONSES

the specification of which

(check one)

☒ is attached hereto.

☐ was filed on _____ as United States Application No. or PCT International Application Number _____ and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)			Priority	Not Claimed
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>	
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>	
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>	

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

_____	_____
(Application Serial No.)	(Filing Date)
_____	_____
(Application Serial No.)	(Filing Date)

_____	_____
(Application Serial No.)	(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

_____	_____	_____
(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)
_____	_____	_____
(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)
_____	_____	_____
(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*

Michael I. Stewart (24,973)

Send Correspondence to: **Michael I. Stewart**
c/o Sim & McBurney
6th Floor, 330 University Avenue, Toronto,
Ontario, Canada, M5G 1R7.

Direct Telephone Calls to: *(name and telephone number)*
(416) 595-1155

Full name of sole or first inventor CHARLES D.Y. SIA	Date
Sole or first inventor's signature	
Residence Thornhill, Ontario, Canada	
Citizenship British	
Post Office Address 189 Mabley Crescent, Thornhill, Ontario, Canada, L4J 2Z7.	

Full name of second inventor, if any PELE CHONG	Date
Second inventor's signature	
Residence Richmond Hill, Ontario, Canada	
Citizenship Canadian	
Post Office Address 32 Estoril Street, Richmond Hill, Ontario, Canada, L4C 0B6.	

Full name of third inventor, if any

MICHEL H. KLEIN

Third inventor's signature

Date

Residence

Willowdale, Ontario, Canada

Citizenship

Canadian

Post Office Address

16 Munro Boulevard, Willowdale, Ontario, Canada, M2P 1B9.

Full name of fourth inventor, if any

Fourth inventor's signature

Date

Residence

Citizenship

Post Office Address

Full name of fifth inventor, if any

Fifth inventor's signature

Date

Residence

Citizenship

Post Office Address

Full name of sixth inventor, if any

Sixth inventor's signature

Date

Residence

Citizenship

Post Office Address

This form is to be filled out by the inventor or the inventor's attorney. It is to be filled out for each inventor. It is to be filled out for each country. It is to be filled out for each country. It is to be filled out for each country.

Figure 1
Stabilization of HLA-A2 molecules on T2 Cells
by HIV-1(LAI)_{Rev} CTL-motif containing peptides





Figure 2.

Immunogenicity of HIV-1(LAI)Rev immunogens in A2Kb transgenic mice



①

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)